Shares of Biogen were up 1.8% in premarket trade Wednesday after the company reported revenue that beat estimates and earnings that were in line with what Wall Street had expected. Profit for the latest quarter rose to $1.409 billion, or $7.15 per share, compared with $1.173 billion, or $5.54 per share, in the year-earlier period. Adjusted EPS was $6.98, matching the FactSet consensus. Revenue was $3.49 billion, above the FactSet consensus of $3.396 billion and higher than $3.131 billion a year ago. The company's best-selling drug, Tecfidera, brought in $999 million, up from $987 million in the year-earlier period. Spinraza, Biogen's blockbuster spinal muscular atrophy drug, brought in $518 million, up from $364 million a year ago. Biogen has had a tough quarter -- shares have fallen 23% so far this year, a plunge sparked by the company's discontinuation of its Phase 3 trials of the Alzheimer's drug aducanumab in March. The S&P 500 /zigman2/quotes/210599714/realtime SPX +1.05% has gained 17%.